Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

261. Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis

Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis Kanis J A, Stevenson M, McCloskey E V, Davis S, Lloyd-Jones M CRD summary Extensive searching revealed only small individual data sets and the review was largely inconclusive. The conclusion that there was insufficient evidence to judge the clinical (...) effectiveness of most interventions for glucocorticoid-induced osteoporosis was reasonable, but the conclusion that risedronate was cost effective in a limited population was based on very sparse effectiveness data and should be viewed with caution. Authors' objectives To assess the clinical effectiveness and cost effectiveness of pharmacological interventions for the prevention and treatment of glucocorticoid-induced osteoporosis. Searching MEDLINE, PreMEDLINE, EMBASE, BIOSIS Previews, CINAHL, The Cochrane

2007 DARE.

262. Performance of the Osteoporosis Self-Assessment Tool in ruling out low bone mineral density in postmenopausal women: a systematic review

Performance of the Osteoporosis Self-Assessment Tool in ruling out low bone mineral density in postmenopausal women: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 DARE.

263. Cost-effectiveness of different strategies for the management of steroid induced osteoporosis

Cost-effectiveness of different strategies for the management of steroid induced osteoporosis Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis Kanis JA, Stevenson M, McCloskey EV, Davis S, Lloyd-Jones M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation Kanis JA, Stevenson M, McCloskey EV, Davis S, Lloyd-Jones M. Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technology Assessment 2007; 11(7): 1-256 Authors' objectives To determine whether strategies can be devised for the assessment and treatment of glucocorticoid-induced osteoporosis (GIO) Authors' conclusions Cost-effective scenarios for risedronate in the management of GIO were identified, but only at the extremes of age and T

2007 Health Technology Assessment (HTA) Database.

264. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. Full Text available with Trip Pro

Teriparatide or alendronate in glucocorticoid-induced osteoporosis. Bisphosphonate therapy is the current standard of care for the prevention and treatment of glucocorticoid-induced osteoporosis. Studies of anabolic therapy in patients who are receiving long-term glucocorticoids and are at high risk for fracture are lacking.In an 18-month randomized, double-blind, controlled trial, we compared teriparatide with alendronate in 428 women and men with osteoporosis (ages, 22 to 89 years) who had (...) of nonvertebral fractures was similar in the two groups (5.6% vs. 3.7%, P=0.36). Significantly more patients in the teriparatide group had at least one elevated measure of serum calcium.Among patients with osteoporosis who were at high risk for fracture, bone mineral density increased more in patients receiving teriparatide than in those receiving alendronate. (ClinicalTrials.gov number, NCT00051558 [ClinicalTrials.gov].).Copyright 2007 Massachusetts Medical Society.

2007 NEJM Controlled trial quality: predicted high

265. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men Full Text available with Trip Pro

Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men Schousboe J T, Taylor B C, Fink H A, Kane R L, Cummings S R, Orwoll E S, Melton L J, Bauer D C, Ensrud K E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study evaluated the use of bone densitometry followed by 5 years of oral bisphosphonate therapy in elderly white men for the treatment of osteoporosis. Type of intervention Diagnosis and treatment. Economic study type Cost-utility analysis. Study population The hypothetical population comprised

2007 NHS Economic Evaluation Database.

266. Persistence, reproducibility, and cost-effectiveness of an intervention to improve the quality of osteoporosis care after a fracture of the wrist: results of a controlled trial

Persistence, reproducibility, and cost-effectiveness of an intervention to improve the quality of osteoporosis care after a fracture of the wrist: results of a controlled trial Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 NHS Economic Evaluation Database.

267. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates

Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 NHS Economic Evaluation Database.

268. Review: no single physical examination sign rules in or out osteoporosis or spinal fracture Full Text available with Trip Pro

Review: no single physical examination sign rules in or out osteoporosis or spinal fracture Review: no single physical examination sign rules in or out osteoporosis or spinal fracture | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: no single physical examination sign rules in or out osteoporosis or spinal fracture Article Text Diagnosis Review: no single physical examination sign rules in or out osteoporosis or spinal fracture Free Olof

2006 Evidence-Based Medicine

269. Osteoporosis. (Abstract)

Osteoporosis. Osteoporosis is a serious public health issue. The past 10 years have seen great advances in our understanding of its epidemiology, pathophysiology, and treatment, and further advances are rapidly being made. Clinical assessment will probably evolve from decisions mainly being made on the basis of bone densitometry, to use of algorithms of absolute fracture risk. Biochemical markers of bone turnover are also likely to become more widely used. Bisphosphonates will probably remain

2006 Lancet

270. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. Full Text available with Trip Pro

Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. Treatment with glucocorticoids is associated with bone loss starting soon after therapy is initiated and an increased risk of fracture.We performed a randomized, double-placebo, double-blind clinical trial of 18 months' duration among patients with a rheumatic disease who were starting glucocorticoids at a daily dose that was equivalent to at least 7.5 mg of prednisone. A total of 201 patients were assigned to receive either

2006 NEJM Controlled trial quality: predicted high

271. What evidence is there for the prevention and screening of osteoporosis?

What evidence is there for the prevention and screening of osteoporosis? WHO/Europe | What evidence is there for the prevention and screening of osteoporosis? S Français Deutsch Pусский M search Databases Interactive atlases Evidence resources European health report Our flagship report maps health trends, charts progress towards achieving health goals and provides an advance base for health policy Resources Social media Events Organization Governance Partners Networks Jobs and internships What (...) evidence is there for the prevention and screening of osteoporosis? What evidence is there for the prevention and screening of osteoporosis? Download Summary The issue Osteoporosis – an excessive decrease in bone mass – is more common in women than in men. It is a particularly common condition among elderly women in affluent countries. Osteoporosis is a risk factor for fractures, which occur most commonly at the wrist, spine and hip. Other important risk factors for fractures include those both related

2006 WHO Health Evidence Network

272. Vertebral assessment with DEXA: Screening for vertebral fracture during risk assessment for osteoporosis

Vertebral assessment with DEXA: Screening for vertebral fracture during risk assessment for osteoporosis National Horizon Scanning Unit Horizon scanning prioritising summary Volume 13, Number 4: Vertebral assessment with DEXA: Screening for vertebral fracture during risk assessment for osteoporosis June 2006 © Commonwealth of Australia 2006 [add ISSN] [add Publications Approval Number] This work is copyright. You may download, display, print and reproduce this material in unaltered form only (...) summary was prepared by Tom Sullivan and Janet Hiller from the National Horizon Scanning Unit, Adelaide Health Technology Assessment, Discipline of Public Health, Mail Drop 511, University of Adelaide, South Australia, 5005. PRIORITISING SUMMARY REGISTER ID: 000209 NAME OF TECHNOLOGY: VERTEBRAL ASSESSMENT WITH DEXA PURPOSE AND TARGET GROUP: SCREENING FOR VERTEBRAL FRACTURE DURING RISK ASSESSMENT FOR OSTEOPOROSIS STAGE OF DEVELOPMENT (IN AUSTRALIA): Yet to emerge Established Experimental ? Established

2006 Australia and New Zealand Horizon Scanning Network

273. Parathyroid hormone for the treatment of osteoporosis: a systematic review

Parathyroid hormone for the treatment of osteoporosis: a systematic review Parathyroid hormone for the treatment of osteoporosis: a systematic review Parathyroid hormone for the treatment of osteoporosis: a systematic review Cranney A, Papaioannou A, Zytaruk N, Hanley D, Adachi J, Goltzman D, Murray T, Hodsman A CRD summary This review concluded that human parathyroid hormone (1-34) used to treat osteoporosis in postmenopausal women with previous fractures is associated with significant (...) increases in bone mineral density and a significant reduction in the risk of new fractures. The authors’ conclusions appear valid, but some caution is advised given the variability and small size of many of the studies. Authors' objectives To assess the efficacy and safety of human parathyroid hormone (hPTH) for the prevention of fracture in osteoporosis. Searching MEDLINE, EMBASE, HTA, Current Contents and the Cochrane Controlled Trials Register were searched from 1966 to September 2005. The search

2006 DARE.

274. Meta-analysis: accuracy of quantitative ultrasound for identifying patients with osteoporosis

Meta-analysis: accuracy of quantitative ultrasound for identifying patients with osteoporosis Meta-analysis: accuracy of quantitative ultrasound for identifying patients with osteoporosis Meta-analysis: accuracy of quantitative ultrasound for identifying patients with osteoporosis Nayak S, Olkin I, Liu H, Grabe M, Gould M K, Allen E, Owens D K, Bravata D M CRD summary This well-conducted and clearly reported review addressed the diagnostic performance of quantitative ultrasound for identifying (...) patients with osteoporosis. The authors' conclusions, that based on currently available data quantitative ultrasound cannot reliably rule-in or rule-out osteoporosis, follow from the data presented. The exclusion of non-English language studies might have resulted in the loss of relevant data. Authors' objectives To determine the diagnostic performance of calcaneal quantitative ultrasound, compared with X-ray absorptiometry, for identifying patients who meet the World Health Organization criteria

2006 DARE.

275. Teriparatide and bisphosphonates for treatment of osteoporosis in women: a clinical and economic analysis

Teriparatide and bisphosphonates for treatment of osteoporosis in women: a clinical and economic analysis Teriparatide and bisphosphonates for treatment of osteoporosis in women: a clinical and economic analysis Teriparatide and bisphosphonates for treatment of osteoporosis in women: a clinical and economic analysis Coyle D, Hadj Tahar A, Murphy G, Perras C, Skidmore B, Boucher M, Husereau D Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Coyle D, Hadj Tahar A, Murphy G, Perras C, Skidmore B, Boucher M, Husereau D. Teriparatide and bisphosphonates for treatment of osteoporosis in women: a clinical and economic analysis. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Technology Report Issue 70. 2006 Authors' objectives The aim of this report is to assess the clinical and cost effectiveness of teriparatide relative

2006 Health Technology Assessment (HTA) Database.

276. Cost-effectiveness strategies to treat osteoporosis in elderly women Full Text available with Trip Pro

Cost-effectiveness strategies to treat osteoporosis in elderly women Cost-effectiveness strategies to treat osteoporosis in elderly women Cost-effectiveness strategies to treat osteoporosis in elderly women Pfister A K, Welch C A, Lester M D, Emmett M K, Saville P D, Duerring S A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology A strategy of screening all women aged 65 years or older for osteoporosis, and treatment for those who tested positive, was evaluated. The treatments considered were: no treatment; daily oral raloxifene, 60 mg; daily nasal calcitonin, 200 U; daily oral bisphosphonates (5 mg risedronate or 10 mg alendronate); and daily injectable recombinant parathyroid hormone (PTH), 20 microg. Calcium supplements

2006 NHS Economic Evaluation Database.

277. Half the burden of fragility fractures in the community occur in women without osteoporosis: when is fracture prevention cost-effective?

Half the burden of fragility fractures in the community occur in women without osteoporosis: when is fracture prevention cost-effective? Half the burden of fragility fractures in the community occur in women without osteoporosis: when is fracture prevention cost-effective? Half the burden of fragility fractures in the community occur in women without osteoporosis: when is fracture prevention cost-effective? Sanders K M, Nicholson G C, Watts J J, Pasco J A, Henry M J, Kotowicz M A, Seeman E (...) Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of anti-resorptive drug therapy to reduce the fracture rate among postmenopausal women at high risk of fracture only (i.e. women with osteoporosis), or the additional treatment

2006 NHS Economic Evaluation Database.

278. Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy raloxifene, or alendronate Full Text available with Trip Pro

Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy raloxifene, or alendronate Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy raloxifene, or alendronate Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy raloxifene, or alendronate Mobley L R, Hoerger T J, Wittenborn J S, Galuska D A, Rao J K Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined a strategy of screening women for osteoporosis at age 65 years, and treatment for those who tested positive. The three alternative treatments considered were hormone replacement therapy (HRT), raloxifene and alendronate. All women were screened using

2006 NHS Economic Evaluation Database.

279. Economic comparison of diagnostic approaches for evaluating osteoporosis in older women

Economic comparison of diagnostic approaches for evaluating osteoporosis in older women Economic comparison of diagnostic approaches for evaluating osteoporosis in older women Economic comparison of diagnostic approaches for evaluating osteoporosis in older women Kraemer D F, Nelson H D, Bauer D C, Helfand M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined three diagnostic strategies for the assessment of osteoporosis in older women. The strategies were: dual-energy X-ray absorptiometry of the hip or femoral neck (DXA-FN) alone; calcaneal quantitative ultrasound (QUS) alone; and a sequential approach with QUS first and then DXA-FN for those with low QUS scores. A T-score of less than or equal to -2.5 was used

2006 NHS Economic Evaluation Database.

280. At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis Full Text available with Trip Pro

At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis Borgstrom F, Johnell O, Kanis J A, Jonsson B, Rehnberg C Record Status This is a critical abstract (...) population The study population comprised postmenopausal women requiring treatment for osteoporosis. Setting The setting was secondary care. The economic study was carried out in seven countries, specifically, Australia, Germany, Japan, Sweden, Spain, the UK and the USA. Dates to which data relate The clinical data came from studies published between 1994 and 2005. No dates for resource use were clearly reported, although much of the data were derived from Swedish sources. The price year was 2004. Source

2006 NHS Economic Evaluation Database.